SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3561 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1685I understand what you are saying. I am bit expanding thinking, what may influencMiljenko Zuanic-11/10/2014
1684For influencing future policy vis-à-vis the LDL biomarker, there’s no reasoDewDiligence_on_SI-11/10/2014
1683Well, trial did experience protocol changes during the course, but standard (LDLMiljenko Zuanic-11/10/2014
1682PP = Per Protocol (also called "On Treatment") analysis.DewDiligence_on_SI-11/10/2014
1681Sorry, help me, what "PP" means (I know what is ITT)? I know, I am sMiljenko Zuanic-11/10/2014
1680We need to distinguish between IMPROVE-IT's ITT results and its PP results; DewDiligence_on_SI-11/10/2014
1679This morning we have good news, AMGN-NDA accepted for review by FDA, for the shoMiljenko Zuanic-11/10/2014
1678Bispecific antibody also not a part of the Sanofi collaboration.Miljenko Zuanic-11/4/2014
1677REGN1500 is an mAb against AngPTL3. Parking some abstracts on this cardiometaboBiotech Jim-11/4/2014
1676No respond to AMGN, no respond to Sanofi,....but surely they (CFO and CEO) are rMiljenko Zuanic-10/29/2014
1675Yesterday announcement of the increase in pts enrolment number in outcome trialMiljenko Zuanic-10/29/2014
1674Parking this meta-analysis on lipids control prior to the release of Improve-It Biotech Jim-10/29/2014
1673Another debacle at Sanofi, CEO is out. Among many things last time they give us Miljenko Zuanic-10/29/2014
1672What lawsuit?Felix B-10/24/2014
1671Canaccord Genuity ups price target for REGN to $460/sh. REGN prints $400+ todayBiotech Jim110/24/2014
1670Parking these articles in advance of the Improve-It trial results on ezetimibe aBiotech Jim-10/23/2014
1669The FIRST word in AMGN public PR was "manufacturing", so it is not tarMiljenko Zuanic-10/21/2014
1668I did not know you could patent the approach of using mAb to various targets. IFelix B-10/21/2014
1667Jim, AMGN priority date is 8-2007, and REGN is 12-2008. If REGN does not have reMiljenko Zuanic-10/19/2014
1666I have now studied the PCSK9 patents by REGN and AMGN, and I have a preliminary Biotech Jim-10/19/2014
1665Thanks for your reply. Do you have a view on the AMGN litigation?Haven't loDewDiligence_on_SI-10/17/2014
1664I will mention two this point. A poster on your board (with a significant groBiotech Jim110/17/2014
1663What are some of the REGN misconceptions you see on other boards? T.i.a. DewDewDiligence_on_SI-10/17/2014
1662Fully agree. These NIH results will only bolster sales in the future. There arBiotech Jim-10/17/2014
1661That's a trifecta on efficacy, dosing frequency and SAEs. PeterBiomaven-10/17/2014
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News